Literature DB >> 6984388

A rapid technique for isolation of viable tumor cells from solid tumors: use of the tumor cells for induction and measurement of cell-mediated cytotoxic responses.

E Kedar, B L Ikejiri, G D Bonnard, R B Herberman.   

Abstract

A rapid and simple technique for the isolation of viable tumor cells from human and mouse solid neoplasms is described. It consists of a 5 to 10-min treatment with trypsin-collagenase-DNase mixture, followed by mechanical disaggregation of the tumor tissue and subsequently by a brief centrifugation on a discontinuous Percoll gradient. With the tumors employed, this procedure usually requires less than 1 hr and results in preparations comprising greater than 80% tumor cells with viability of 80-90%. Cell-mediated cytotoxic response was measured with: (a) unsensitized lymphocytes freshly obtained from tumor-bearing hosts; (b) lymphocytes propagated in culture with T cell growth factor; and (c) lymphocytes stimulated in cocultures with autologous or syngeneic tumor cells. The cytotoxic activity was assessed in a modified [51Cr]-release assay adapted for solid tumor cells, allowing a long incubation period (24 hr) and the use of a low number (200-1000) of highly labeled target cells (2-10 counts/min/cell).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6984388     DOI: 10.1016/0277-5379(82)90248-6

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  17 in total

1.  Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.

Authors:  Z Gazit; D W Weiss; D Shouval; M Yechezkeli; V Schirrmacher; M Notter; J Walter; E Kedar
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Comparison of recombinant-interleukin-2-activated peripheral blood and tumor-infiltrating lymphocytes of patients with epithelial ovarian carcinoma: cytotoxicity, growth kinetics and phenotype.

Authors:  E Lotzová; C A Savary; R S Freedman; C L Edwards; M Morris
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Signalling pathway of tumor necrosis factor in normal and tumor cells.

Authors:  N Watanabe; H Neda; Y Ohtusuka; H Sone; N Yamauchi; M Maeda; H Kuriyama; Y Niitsu
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Effect of virus-modified tumor cell extracts, autologous mononuclear cell infusions and interleukin-2 on oncolytic activity of effector cells of patients with advanced ovarian cancer.

Authors:  K Furukawa; E Lotzová; R S Freedman; J B Bowen; C L Edwards; J T Wharton
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Elevated IL-13Ralpha2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway.

Authors:  Debasmita Mandal; Alan D Levine
Journal:  Inflamm Bowel Dis       Date:  2010-05       Impact factor: 5.325

6.  Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo.

Authors:  G Schulz; T F Bumol; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

7.  Natural cell-mediated cytotoxicity in vitro and inhibition of tumor growth in vivo by murine lymphoid cells cultured with T cell growth factor (TCGF).

Authors:  E Kedar; B L Ikejiri; E Gorelik; R B Herbermann
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

8.  Methods for amplifying the induction and expression of cytotoxic response in vitro to syngeneic and autologous freshly-isolated solid tumors of mice.

Authors:  E Kedar; E Chriqui-Zeira; S Mitelman
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

9.  Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization.

Authors:  A Mazumder; E A Grimm; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

10.  DNA cell-cycle analysis of cervical cancer by flow cytometry using simultaneous cytokeratin labelling for identification of tumour cells.

Authors:  R Kimmig; T Kapsner; H Spelsberg; M Untch; H Hepp
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.